Duncker Streett & CO Inc Vertex Pharmaceuticals Inc Transaction History
Duncker Streett & CO Inc
- $542 Million
- Q2 2025
A detailed history of Duncker Streett & CO Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Duncker Streett & CO Inc holds 7,732 shares of VRTX stock, worth $3.62 Million. This represents 0.64% of its overall portfolio holdings.
Number of Shares
7,732
Previous 7,747
0.19%
Holding current value
$3.62 Million
Previous $3.76 Million
8.34%
% of portfolio
0.64%
Previous 0.75%
Shares
10 transactions
Others Institutions Holding VRTX
# of Institutions
1,826Shares Held
231MCall Options Held
1.49MPut Options Held
1.07M-
Capital World Investors Los Angeles, CA28.5MShares$13.4 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.5MShares$11 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.98 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$6.81 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.52 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $120B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...